These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 1517791

  • 1. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.
    Markman M, Reichman B, Hakes T, Lewis JL, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W.
    J Clin Oncol; 1992 Sep; 10(9):1479-84. PubMed ID: 1517791
    [Abstract] [Full Text] [Related]

  • 2. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M, Reichman B, Hakes T, Rubin S, Lewis JL, Jones W, Barakat R, Curtin J, Almadrones L, Hoskins W.
    Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
    [Abstract] [Full Text] [Related]

  • 3. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
    Markman M, Blessing JA, Major F, Manetta A.
    Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734
    [Abstract] [Full Text] [Related]

  • 4. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R.
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [Abstract] [Full Text] [Related]

  • 5. Salvage therapy in ovarian cancer: is there a role for intraperitoneal drug delivery?
    Markman M.
    Gynecol Oncol; 1993 Oct; 51(1):86-9. PubMed ID: 8244180
    [Abstract] [Full Text] [Related]

  • 6. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
    Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, Almadrones L, Ochoa M, Chapman D, Saigo P.
    J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
    [Abstract] [Full Text] [Related]

  • 7. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.
    Markman M, Reichman B, Hakes T, Jones W, Lewis JL, Rubin S, Almadrones L, Hoskins W.
    J Clin Oncol; 1991 Oct; 9(10):1801-5. PubMed ID: 1919630
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins W, Markman M.
    Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
    [Abstract] [Full Text] [Related]

  • 9. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.
    Nardi M, Cognetti F, Pollera CF, Giulia MD, Lombardi A, Atlante G, Calabresi F.
    J Clin Oncol; 1990 Jun; 8(6):1036-41. PubMed ID: 2189953
    [Abstract] [Full Text] [Related]

  • 10. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
    Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A.
    Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
    [Abstract] [Full Text] [Related]

  • 11. Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate.
    Markman M, Reichman B, Hakes T, Barakat R, Curtin J, Rubin S, Jones W, Lewis JL, Almadrones L, Hoskins W.
    J Cancer Res Clin Oncol; 1992 Dec; 118(3):235-7. PubMed ID: 1548290
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.
    Muggia FM, Liu PY, Alberts DS, Wallace DL, O'Toole RV, Terada KY, Franklin EW, Herrer GW, Goldberg DA, Hannigan EV.
    Gynecol Oncol; 1996 Jun; 61(3):395-402. PubMed ID: 8641622
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ, Braly P, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Najera L, Johnson D, Doroshow JH.
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [Abstract] [Full Text] [Related]

  • 18. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H.
    Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
    [Abstract] [Full Text] [Related]

  • 19. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.
    Howell SB, Kirmani S, McClay EF, Kim S, Braly P, Plaxe S.
    Semin Oncol; 1991 Feb; 18(1 Suppl 3):5-10. PubMed ID: 2003227
    [Abstract] [Full Text] [Related]

  • 20. Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy.
    Markman M, Jones W, Lewis JL, Rubin S, Hakes T, Reichman B, Barakat R, Curtin J, Almadrones L, Hoskins W.
    J Cancer Res Clin Oncol; 1992 Feb; 118(2):163-5. PubMed ID: 1735737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.